Novo Nordisk Investor Presentation - First Nine Months of 2016

Closing remarks Investor presentation First nine months of 2016 Slide 20 • 27% Solid market performance value market share in diabetes care and solid leadership position • ~4% annual insulin volume growth • 46% insulin volume market share with leadership position across all regions • >20% annual GLP-1 volume growth • 53% GLP-1 volume market share with strong global leadership position Promising pipeline • The only company with a full portfolio of novel insulin and GLP-1 products • Semaglutide portfolio offers expansion opportunity with both injectable and oral administration XultophyⓇ supports promising outlook for insulin and GLP-1 combination therapy • SaxendaⓇ and multiple early stage development projects hold potential within obesity • Broad pipeline within haemophilia and growth hormone disorders Source: IMS MAT August 2016 volume and value (DKK) figures changing diabetes novo nordisk

View entire presentation